Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 54.39
-0.802 %
$ 178 M
Market Cap
13.73
P/E
1. INTRINSIC VALUE
Balance Sheet
Utah Medical Products, Inc.
| Current Assets | 96.3 M |
| Cash & Short-Term Investments | 83 M |
| Receivables | 4.09 M |
| Other Current Assets | 9.26 M |
| Non-Current Assets | 26.2 M |
| Long-Term Investments | 0 |
| PP&E | 9.76 M |
| Other Non-Current Assets | 16.4 M |
| Current Liabilities | 3.76 M |
| Accounts Payable | 543 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 3.21 M |
| Non-Current Liabilities | 1.35 M |
| Long-Term Debt | 282 K |
| Other Non-Current Liabilities | 1.07 M |
EFFICIENCY
Earnings Waterfall
Utah Medical Products, Inc.
| Revenue | 40.9 M |
| Cost Of Revenue | 16.8 M |
| Gross Profit | 24.1 M |
| Operating Expenses | 10.5 M |
| Operating Income | 13.6 M |
| Other Expenses | -280 K |
| Net Income | 13.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Utah Medical Products, Inc.
| Net Income | 13.9 M |
| Depreciation & Amortization | 2.77 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 256 K |
| Change in Working Capital | 0 |
| Others | -14.1 M |
| Free Cash Flow | 0 |
Wall Street Analysts Price Targets
Utah Medical Products, Inc.
UTMD has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
0.50%
DIVIDEND YIELD
0.305 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Utah Medical Products, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
accessnewswire.com
- 2 months ago
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
zacks.com
- 2 months ago
UTMD Reports Year 2024 and Fourth Quarter Financial Performance
SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.
accessnewswire.com
- 2 months ago
Utah Medical Products: Favorably Skewed Risk/Reward Profile
UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share.
seekingalpha.com
- 3 months ago
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S.
accesswire.com
- 5 months ago
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales
UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.
zacks.com
- 5 months ago
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024
SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
accesswire.com
- 5 months ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
accesswire.com
- 8 months ago
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
zacks.com
- 8 months ago
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
accesswire.com
- 8 months ago
Zacks Initiates Coverage of UTMD With Neutral Recommendation
Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.
zacks.com
- 10 months ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / May 7, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on July 5, 2024 to stockholders of record at the close of business on June 14, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
accesswire.com
- 11 months ago
8. Profile
Summary
Utah Medical Products, Inc. UTMD
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 178 M
Dividend Yield
0.50%
Description
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Contact
7043 South 300 West, Midvale, UT, 84047-1048
https://www.utahmed.com
IPO
Date
March 8, 1999
Employees
155
Officers
Mr. Brian L. Koopman
Principal Financial Officer, Accounting Manager & Controller
Marcena H. Clawson
Head of Corporate Sales
Mark L. Fox
Vice President of Marketing
Mr. Kevin L. Cornwell
Chairman, Chief Executive Officer, President & Secretary